Phase Ib trial reveals TLL-018 improves outcomes in patients with chronic spontaneous urticaria, suggesting new treatment options.
TLL-018 was well-tolerated and effective in treating moderate-to-severe CSU in patients who had an inadequate response to antihistamines.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: